Arrakis Therapeutics is a biopharmaceutical company pioneering RNA-targeted small molecules (rSMs) as a new class of genetic medicines. Its rSM platform enables orally available small molecules to bind RNA and modulate previously undruggable biological pathways, with an industrialized discovery toolkit spanning multiple modalities. - View it on GitHub